Cloud-Clone ELISA kits used in two oral medicine studies

Cloud-Clone says its assay kits supported two 2026 oral-medicine papers from leading Chinese research teams, including studies on oral tumor targeting and MRSA-linked cancer progression. The company is also promoting CRO services and oral-disease research models as part of a broader one-stop lab offering.

Why it matters: - Cloud-Clone is positioning its ELISA kits and research services for oral-disease work that spans mechanistic biology, pre-clinical testing and translational research. - The company says its reagents were used in two high-impact 2026 studies, a signal meant to reinforce product credibility in demanding research settings. - Oral-disease research has become more important as prevention, precision intervention and public-health awareness have expanded.

What happened: - In June 2026, researchers from Peking University School of Stomatology published a paper in Journal of Extracellular Vesicles on a CD6-targeted vesicle system for delivering IL24 mRNA against tumors. - In July 2026, scientists from West China Hospital of Stomatology, Sichuan University, and the State Key Laboratory of Oral Diseases published a paper in Journal of Advanced Research on methicillin-resistant Staphylococcus aureus extracellular vesicles and oral squamous cell carcinoma. - Cloud-Clone says both studies used its assay kits. - The company says the publications validate the reliability and research value of its reagents in advanced oral-medicine work.

The details: - The Peking University team used the Cloud-Clone Mouse IL-24 ELISA Kit, Cat. No. SEC064Mu, to measure IL-24 protein in animal organ and tumor tissue samples. - That dataset supported evaluation of delivery-vehicle targeting, in-vivo anti-tumor pharmacodynamics and biosafety. - The study examined cell-membrane vesicles enriched with CD6 and designed to deliver IL24 mRNA to CD166-positive colorectal carcinoma and squamous-cell carcinoma. - The West China Hospital study used the Cloud-Clone Human IL-8 ELISA Kit, Cat. No. SEA080Hu, and Human MCP-1 (CCL2) ELISA Kit, Cat. No. SEA087Hu. - Those kits measured analytes in cell-culture supernatants from OSCC cells treated with S. aureus extracellular vesicles for 24 and 48 hours. - The MRSA study found that MRSA-derived extracellular vesicles entered OSCC cells, increased proliferation and tumor growth, and activated the ERK/c-Jun pathway. - The paper also linked MRSA vesicles to increased IL-8, CXCR1 signaling, IL-2 production and JAK/STAT5A activation. - Genetic deletion of IL-8 or blocking the IL-8-CXCR1 interaction reduced the tumor-promoting effects in ectopic mouse models. - Cloud-Clone says its ELISA kits performed reliably across tumor-tissue homogenates and cell-culture supernatants.

Between the lines: - The announcement is as much a business-development pitch as a research update. - Cloud-Clone is using published work to argue that its products hold up in complex biological samples, which is often a key buying criterion for labs. - The company is also signaling that it can support projects beyond reagents by offering a broader outsourced research workflow.

What's next: - Cloud-Clone says it will continue expanding its product and service portfolio. - The company is offering custom service inquiries and technical support for researchers seeking specifications, technical parameters or project help. - Cloud-Clone is promoting oral-disease research resources, including periodontitis animal models, gingival tissue formats and multiple primary cell types. - The company says its CRO workflow covers experimental design, project confirmation, execution, data analysis and final report delivery. - Cloud-Clone is framing its offering as an integrated in-vitro-to-in-vivo system for oral inflammation and periodontal-tissue regeneration research.